Access to and affordability of cancer medicines: time to focus on the last mile
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference9 articles.
1. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey;Fundytus;Lancet Oncol,2021
2. Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies;Youn;Health Serv Res,2021
3. The selection of essential drugs: report of a WHO expert committee [meeting held in Geneva from 17 to 21 October 1977],1977
4. What level of domestic government health expenditure should we aspire to for universal health coverage?;Mcintyre;Health Econ Policy Law,2017
5. Prices of patented medicines in India;Joseph;Econ Polit Wkly,2018
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10
2. Access to colorectal cancer screening in populations in China, 2020: A coverage‐focused synthesis analysis;International Journal of Cancer;2024-03-30
3. Acute graft-versus-host disease;Nature Reviews Disease Primers;2023-06-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3